Skye Bioscience, Inc.

US$0.99As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:SKYEHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR (51.08%)
Div yield —
ROE (233.87%)
Biotechnology
Beta (5Y) 3.15
PE TTM —
TSR TTM (92.01%)
Mkt cap US$4.385M
ROIC (137.38%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$1.25
25.72%
50.58%
Sell 3|4|1|2|2
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.01
0.01
0.01
0.01
(3.18%)
(6.47%)
(3.37%)
0.85%
Revenue$M
0.372
0.375
0.372
0.386
8.72%
9.01%
10.45%
9.61%
Peers (US$4.385M)
Cap (US$)
PE
4.439M
—
4.354M
—
Capital
TTM
5Y
10Y
Leveragex
10.32
(0.153)
(0.085)
EBIT/Intx
2.332
0.870
0.852
Own earn%
(224.29)
(40.11)
(40.15)
Sh yield%
28.17
42.83
40.63
Owners
Insiders/Inst%
11.83
71.02
Short interest%
3.26
SBC / revenue%
5.48
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
24
Op margin range%
30–35
$1 testx
0.0
Incr. ROIC%
10